Ibrutinib: Phase III started

Pharmacyclics enrolled the fifth patient in the open-label, international Phase III RESONATE-2 trial comparing 420 mg oral ibrutinib daily vs. oral chlorambucil given on days 1 and 15

Read the full 281 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE